BOONTON, N.J.--(BUSINESS WIRE)--Unigene Laboratories, Inc. (OTCBB: UGNE, http://www.unigene.com) announced that, following its end-of-Phase II meeting and subsequent discussions with the US Food and Drug Administration (FDA), it has reached an understanding relating to the key design parameters of a pivotal Phase III study for an oral calcitonin product formulated using its Enteripep® oral delivery technology. The following elements of the study have been established:
